Levine B, Svoboda J, Nasta S, Porter D, Chong E, Lacey S, Mahnke Y, Melenhorst J, Chew A, Shah G, Hasskar J, Wasik M, Landsburg D, Mato A, Garfall A, Frey N, Shaw P, Marcucci K, Shea J, McConville H, Manvar N, O'Rourke M, Lamontagne A, Bersenev A, Zheng Z, Schuster S, June C. Chimeric antigen receptor modified T cells directed against CD19 (CTL019) induce clinical responses in patients with relapsed or refractory CD19+ lymphomas. Cytotherapy 2015, 17: s13. DOI: 10.1016/j.jcyt.2015.03.327.Peer-Reviewed Original Research